Novavax Inc. Company Profile
NASDAQ: NVAXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Pre-market: 11.13 +1.09%
Novavax at a glance
Novavax Inc. (NASDAQ: NVAX) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Gaithersburg, MD. Novavax is led by Mr. John Charles Jacobs M.B.A. and employs about 749 people. At a market capitalization of $1.85 billion, it is considered a small-cap company.
Its SEC Central Index Key (CIK) is 0001000694, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Novavax do?
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Business description based on the company's public filings.
Company information
- Legal name
- Novavax Inc.
- Ticker
- NASDAQ: NVAX
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. John Charles Jacobs M.B.A.
- Employees
- 749
- Headquarters
- 21 Firstfield Road, Gaithersburg, MD, United States
- Phone
- 240 268 2000
- Website
- novavax.com
- Market cap
- $1.85B
- SEC CIK
- 0001000694
Companies similar to Novavax
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| VIRVir Biotechnology Inc. | 11.12 | -3.47% | $1.88B | vs NVAX |
| MESOMesoblast Limited ADR | 13.75 | -1.36% | $1.79B | vs NVAX |
| ALVOAlvotech | 5.67 | -3.08% | $2.02B | vs NVAX |
| VCELVericel Corporation | 40.05 | -1.69% | $2.05B | vs NVAX |
| RXRXRecursion Pharmaceuticals Inc. Class A | 3.95 | -7.49% | $2.12B | vs NVAX |
| BCRXBioCryst Pharmaceuticals Inc. | 8.29 | -1.31% | $2.12B | vs NVAX |
| IMCRImmunocore Holdings plc ADR | 29.09 | -1.09% | $1.50B | vs NVAX |
| TSHATaysha Gene Therapies Inc. | 4.43 | 0.00% | $1.44B | vs NVAX |